Hodgkin Lymphoma News and Research

RSS

Three early-phase clinical studies show promising initial data for patients with lymphoma, gastric cancers

Three early-phase clinical studies presented by researchers from The University of Texas MD Anderson Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2024 show promising initial data for patients with lymphoma, gastric or gastroesophageal junction cancers, and specific molecularly selected tumors.

10 Apr 2024

ACE inhibitors show no benefit in reducing chemotherapy-induced heart damage

Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment with high-dose anthracycline chemotherapy did not show any difference in troponin T levels, a biomarker associated with heart damage, at one month after their last chemotherapy dose compared with those who did not take an ACE inhibitor, according to a study presented at the American College of Cardiology's Annual Scientific Session.

8 Apr 2024

Therapeutic potential of CD20 x CD3 bispecific antibodies

On Monday, March 25th, 2024, the U.S. FDA declined approval for Regeneron’s Odronextamab for two forms of lymphoma due to concerns over the progress of ongoing confirmatory trials.

From Sino Biological Inc. 5 Apr 2024

Eating soy products linked to lower cancer risk, study finds

Soy product consumption, particularly tofu and soymilk, is linked to a reduced risk of certain cancers, highlighting the dietary factor's potential protective effect against the disease.

1 Apr 2024

Longer durations of breastfeeding lowers the risk of childhood cancers

Whether duration of breastfeeding was associated with a lower risk of childhood cancers.

28 Mar 2024

Research from NY highlights pollution as a key factor in rising cancer rates among youth

Cancer incidence trends among adults in the New York State (NYS) and associations with common population-level exposures.

28 Mar 2024

New analysis sheds light on cancer incidence and mortality trends in the UK

Trends in cancer incidence and deaths in the United Kingdom (UK) among individuals aged between 35 and 69 years.

14 Mar 2024

Toxic gas that sterilizes medical devices prompts safety rule update

Over the past two years, Madeline Beal has heard frustration and even bewilderment during public meetings about ethylene oxide, a cancer-causing gas that is used to sterilize half of the medical devices in the U.S.

29 Feb 2024

Unintentional weight loss linked to increased risk of cancer diagnosis

Unintentional weight loss is associated with an increase in the risk of a cancer diagnosis within the coming year, according to a study from Dana-Farber Cancer Institute.

23 Jan 2024

Cord blood-derived CAR NK cell therapy targeting CD19 shows promise for treating patients with B-cell malignancies

Researchers from The University of Texas MD Anderson Cancer Center reported promising results in a Phase I/II trial of 37 patients with relapsed or refractory B-cell malignancies who were treated with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting CD19.

18 Jan 2024

$Lisocabtagene maraleucel: A cost-effective second-line treatment for relapsed/refractory DLBCL$

Lisocabtagene maraleucel: A cost-effective second-line treatment for relapsed/refractory DLBCL

Lisocabtagene maraleucel (liso-cel), a CAR T-cell therapy, is a cost effective second line treatment for relapsed and refractory (hard to treat) diffuse large B-cell lymphoma (r/r DLBCL), according to a study published today in Blood Advances.

28 Dec 2023

Spatial profiling predicts recurrence of Hodgkin lymphoma after bone marrow transplant

Cedars-Sinai Cancer investigators have discovered a new way to predict whether a cancer of the immune system will recur in patients treated with a bone marrow transplant.

22 Dec 2023

Brazilian review explores emerging therapies for advanced Hodgkin lymphoma

A new review paper was published in Oncotarget's Volume 14 on December 12, 2023, entitled, "Current perspectives on the management of refractory or relapsed classic Hodgkin lymphoma in Brazil: Balancing efficacy, safety, and tolerability."

20 Dec 2023

Researchers find powerful combo weapon against aggressive lymphoma

The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival (PFS) and achieved an overall remission rate in 82% of patients with relapsed/refractory mantle cell lymphoma (MCL), according to researchers at The University of Texas MD Anderson Cancer Center. Results from the Phase III SYMPATICO trial were presented at the 2023 American Society of Hematology (ASH) Annual Meeting.

12 Dec 2023

New combination treatment offers hope for older patients with mantle cell lymphoma

The phase 2 trial PrE0405 met its primary endpoint, achieving a complete response (CR) rate of 85% in 33 patients over the age of 60 with mantle cell lymphoma (MCL) who received bendamustine and rituximab, a standard chemo-immunotherapy treatment, along with venetoclax, which is investigational in this setting.

11 Dec 2023

New antibody combination shows 'surprising' results in high-risk follicular lymphoma trial

Researchers conducting a Phase 2 clinical trial at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine say a new combination of antibody therapies produced a 'surprisingly high' response rate in patients with high-risk follicular lymphoma, a type of non-Hodgkin lymphoma.

11 Dec 2023

Study reveals genetic roots of hodgkin lymphoma, offering hope for new treatments

A Stanford Medicine-led, international study of hundreds of samples from patients with Hodgkin lymphoma has shown that levels of tumor DNA circulating in their blood can identify who is responding well to treatment and others who are likely to experience a disease recurrence -; potentially letting some patients who are predicted to have favorable outcomes forgo lengthy treatment.

11 Dec 2023

Phase I clinical trial of new CAR T cell therapy AT101 shows promising early responses

Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100 percent complete response (CR) rate at the higher dose levels studied in the trial, according to researchers from the University of Pennsylvania Perelman School of Medicine and Penn Medicine's Abramson Cancer Center.

11 Dec 2023

Study shows linear associations between body mass index and site-specific tumors in young males

The associations between body mass index (BMI) among young males and new-onset site-specific tumors.

8 Nov 2023

Targeted drug may offer a new treatment option for patients with relapsed blood cancer

A new targeted drug, studied by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), may offer a new treatment option for patients with blood cancers, including chronic lymphocytic leukemia (CLL) and Non-Hodgkin lymphoma (NHL) whose disease has stopped responding to standard treatments.

6 Nov 2023

Hodgkin Lymphoma News and Research

Three early-phase clinical studies show promising initial data for patients with lymphoma, gastric cancers

ACE inhibitors show no benefit in reducing chemotherapy-induced heart damage

Therapeutic potential of CD20 x CD3 bispecific antibodies

Eating soy products linked to lower cancer risk, study finds

Longer durations of breastfeeding lowers the risk of childhood cancers

Research from NY highlights pollution as a key factor in rising cancer rates among youth

New analysis sheds light on cancer incidence and mortality trends in the UK

Toxic gas that sterilizes medical devices prompts safety rule update

Unintentional weight loss linked to increased risk of cancer diagnosis

Cord blood-derived CAR NK cell therapy targeting CD19 shows promise for treating patients with B-cell malignancies

Lisocabtagene maraleucel: A cost-effective second-line treatment for relapsed/refractory DLBCL

Spatial profiling predicts recurrence of Hodgkin lymphoma after bone marrow transplant

Brazilian review explores emerging therapies for advanced Hodgkin lymphoma

Researchers find powerful combo weapon against aggressive lymphoma

New combination treatment offers hope for older patients with mantle cell lymphoma

New antibody combination shows 'surprising' results in high-risk follicular lymphoma trial

Study reveals genetic roots of hodgkin lymphoma, offering hope for new treatments

Phase I clinical trial of new CAR T cell therapy AT101 shows promising early responses

Study shows linear associations between body mass index and site-specific tumors in young males

Targeted drug may offer a new treatment option for patients with relapsed blood cancer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News